BioWorld

Sep. 30, 2005

Cypress' Stock Plunges After Phase III Miss In Fibromyalgia

Cypress Bioscience Inc. lost more than half its value Thursday after announcing that a pivotal Phase III study of milnacipran missed its primary endpoint as a treatment for pain associated with fibromyalgia. (BioWorld Today) Read More

Sirna's RNAi Work Lands $250M Deal With Allergan

New Research: Target Host Cells To Help Fight Viruses

Avalon Sets IPO Price: $28.9M Pipeline Boost

Genomic Health's IPO Adds $60M For Breast Cancer Test

Other News To Note

Appointments And Advancements

U.S. Patent Disclosures

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...